Marktanalyse - Ophthalmology Drug Development Pipeline Review, 2016

GBI Research
12.2016
633 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Ophthalmology Drug Development Pipeline Review, 2016


Summary


Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness if not adequately treated.

Although there is a high degree of failure and uncertainty within the R&D of pharmaceuticals, there is a great deal of interest in ophthalmology development. Overall, there are over 700 products in active development in the ophthalmology therapy area, making it one of the largest therapy area pipelines.

Although two thirds of products in development for ophthalmology disorders are at the Discovery or Preclinical stage of development, the number of drugs in the pipeline is very high, creating strong potential for a blockbuster drug to enter the market.

The report provides comprehensive information on the pipeline development landscape for glaucoma, age-related macular degeneration, diabetic retinopathy, diabetic macular edema and keratoconjunctivitis sicca (dry eye), from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.


Scope

- Which companies are the most active within the pipeline for ophthalmology?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have occurred in ophthalmology?


Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 13

2 Introduction 15

2.1 Ophthalmology Therapeutics Report Coverage 15

3 Therapeutics Development by Stage 18

3.1 Age Related Macular Degeneration 18

3.2 Diabetic Retinopathy 20

3.3 Diabetic Macular Edema 22

3.4 Keratoconjunctivitis sicca (Dry Eye) 24

3.5 Glaucoma 26

4 Therapeutics under Development by Companies 28

4.1 Age Related Macular Degeneration 28

4.2 Diabetic Retinopathy 39

4.3 Diabetic Macular Edema 42

4.4 Keratoconjunctivitis sicca (Dry Eye) 46

4.5 Glaucoma 50

5 Therapeutics under Investigation by Universities/Institutes 56

5.1 Age Related Macular Degeneration 56

5.2 Diabetic Retinopathy 57

5.3 Diabetic Macular Edema 57

5.4 Keratoconjunctivitis sicca (Dry Eye) 58

5.5 Glaucoma 58

6 Pipeline Products Glance 60

6.1 Age Related Macular Degeneration 60

6.2 Diabetic Retinopathy 64

6.3 Diabetic Macular Edema 66

6.4 Keratoconjunctivitis sicca (Dry Eye) 69

6.5 Glaucoma 72

7 Products under Development by Companies 76

7.1 Age Related Macular Degeneration 76

7.2 Diabetic Retinopathy 90

7.3 Diabetic Macular Edema 94

7.4 Keratoconjunctivitis sicca (Dry Eye) 98

7.5 Glaucoma 102

8 Products under Investigation by Universities/Institutes 108

8.1 Age Related Macular Degeneration 108

8.2 Diabetic Retinopathy 109

8.3 Diabetic Macular Edema 110

8.4 Keratoconjunctivitis sicca (Dry Eye) 110

8.5 Glaucoma 111

9 Companies Involved in Therapeutics Development 112

9.1 Age Related Macular Degeneration 112

9.2 Diabetic Retinopathy 173

9.3 Diabetic Macular Edema 194

9.4 Keratoconjunctivitis sicca (Dry Eye) 213

9.5 Glaucoma 231

10 Therapeutics Assessment 290

10.1 Age Related Macular Degeneration 290

10.2 Diabetic Retinopathy 310

10.3 Diabetic Macular Edema 322

10.4 Keratoconjunctivitis sicca (Dry Eye) 335

10.5 Glaucoma 353

11 Recent Pipeline Updates 373

11.1 Age Related Macular Degeneration 373

11.2 Diabetic Retinopathy 496

12 Dormant Projects 541

12.1 Age Related Macular Degeneration 541

12.2 Diabetic Retinopathy 555

12.3 Diabetic Macular Edema 561

12.4 Keratoconjunctivitis sicca (Dry Eye) 564

12.5 Glaucoma 570

13 Discontinued Products 577

13.1 Age Related Macular Degeneration 577

13.2 Diabetic Retinopathy 578

13.3 Diabetic Macular Edema 579

13.4 Keratoconjunctivitis sicca (Dry Eye) 580

13.5 Glaucoma 581

14 Product Development Milestones 583

14.1 Age Related Macular Degeneration 583

14.2 Diabetic Retinopathy 590

14.3 Diabetic Macular Edema 597

14.4 Keratoconjunctivitis sicca (Dry Eye) 607

14.5 Glaucoma 618

15 Appendix 632

15.1 Research Methodology 632

15.2 Secondary Research 632

15.3 Contact Us 633

15.4 Disclaimer 633





1.1 List of Tables

Table 1: Number of Products under Development for Age Related Macular Degeneration 18

Table 2: Number of Products under Development for Age Related Macular Degeneration — Comparative Analysis 19

Table 3: Number of Products under Development for Diabetic Retinopathy 20

Table 4: Number of Products under Development for Diabetic Retinopathy — Comparative Analysis 21

Table 5: Number of Products under Development for Diabetic Macular Edema 22

Table 6: Number of Products under Development for Diabetic Macular Edema — Comparative Analysis 23

Table 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) 24

Table 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) — Comparative Analysis 25

Table 9: Number of Products under Development for Glaucoma, H2 2016 26

Table 10: Number of Products under Development for Glaucoma — Comparative Analysis, H2 2016 27

Table 11: Number of Products under Development by Companies 29

Table 12: Number of Products under Development by Companies (Contd..1) 30

Table 13: Number of Products under Development by Companies (Contd..2) 31

Table 14: Number of Products under Development by Companies (Contd..3) 32

Table 15: Number of Products under Development by Companies (Contd..4) 33

Table 16: Number of Products under Development by Companies (Contd..5) 34

Table 17: Number of Products under Development by Companies (Contd..6) 35

Table 18: Number of Products under Development by Companies (Contd..7) 36

Table 19: Number of Products under Development by Companies (Contd..8) 37

Table 20: Number of Products under Development by Companies (Contd..9) 38

Table 21: Number of Products under Development by Companies 39

Table 22: Number of Products under Development by Companies (Contd..1) 40

Table 23: Number of Products under Development by Companies (Contd..2) 41

Table 24: Number of Products under Development by Companies 43

Table 25: Number of Products under Development by Companies (Contd..1) 44

Table 26: Number of Products under Development by Companies (Contd..2) 45

Table 27: Number of Products under Development by Companies 47

Table 28: Number of Products under Development by Companies (Contd..1) 48

Table 29: Number of Products under Development by Companies (Contd..2) 49

Table 30: Number of Products under Development by Companies, H2 2016 51

Table 31: Number of Products under Development by Companies, H2 2016 (Contd..1) 52

Table 32: Number of Products under Development by Companies, H2 2016 (Contd..2) 53

Table 33: Number of Products under Development by Companies, H2 2016 (Contd..3) 54

Table 34: Number of Products under Development by Companies, H2 2016 (Contd..4) 55

Table 35: Number of Products under Investigation by Universities/Institutes 56

Table 36: Number of Products under Investigation by Universities/Institutes 57

Table 37: Number of Products under Investigation by Universities/Institutes 57

Table 38: Number of Products under Investigation by Universities/Institutes 58

Table 39: Number of Products under Investigation by Universities/Institutes, H2 2016 59

Table 40: Comparative Analysis by Late Stage Development 60

Table 41: Comparative Analysis by Clinical Stage Development 61

Table 42: Comparative Analysis by Early Stage Development 62

Table 43: Comparative Analysis by Unknown Stage Development 63

Table 44: Comparative Analysis by Clinical Stage Development 64

Table 45: Comparative Analysis by Early Stage Development 65

Table 46: Comparative Analysis by Unknown Stage Development 65

Table 47: Comparative Analysis by Late Stage Development 66

Table 48: Comparative Analysis by Clinical Stage Development 67

Table 49: Comparative Analysis by Early Stage Development 68

Table 50: Comparative Analysis by Unknown Stage Development 68

Table 51: Comparative Analysis by Late Stage Development 69

Table 52: Comparative Analysis by Clinical Stage Development 70

Table 53: Comparative Analysis by Early Stage Development 71

Table 54: Comparative Analysis by Unknown Stage Development 71

Table 55: Comparative Analysis by Late Stage Development, H2 2016 72

Table 56: Comparative Analysis by Clinical Stage Development, H2 2016 73

Table 57: Comparative Analysis by Early Stage Development, H2 2016 74

Table 58: Comparative Analysis by Unknown Stage Development, H2 2016 75

Table 59: Products under Development by Companies 76

Table 60: Products under Development by Companies (Contd..1) 77

Table 61: Products under Development by Companies (Contd..2) 78

Table 62: Products under Development by Companies (Contd..3) 79

Table 63: Products under Development by Companies (Contd..4) 80

Table 64: Products under Development by Companies (Contd..5) 81

Table 65: Products under Development by Companies (Contd..6) 82

Table 66: Products under Development by Companies (Contd..7) 83

Table 67: Products under Development by Companies (Contd..8) 84

Table 68: Products under Development by Companies (Contd..9) 85

Table 69: Products under Development by Companies (Contd..10) 86

Table 70: Products under Development by Companies (Contd..11) 88

Table 71: Products under Development by Companies 90

Table 72: Products under Development by Companies (Contd..1) 91

Table 73: Products under Development by Companies (Contd..2) 92

Table 74: Products under Development by Companies (Contd..3) 93

Table 75: Products under Development by Companies 94

Table 76: Products under Development by Companies (Contd..1) 95

Table 77: Products under Development by Companies (Contd..2) 96

Table 78: Products under Development by Companies 98

Table 79: Products under Development by Companies (Contd..1) 99

Table 80: Products under Development by Companies (Contd..2) 100

Table 81: Products under Development by Companies (Contd..3) 101

Table 82: Products under Development by Companies, H2 2016 102

Table 83: Products under Development by Companies, H2 2016 (Contd..1) 103

Table 84: Products under Development by Companies, H2 2016 (Contd..2) 104

Table 85: Products under Development by Companies, H2 2016 (Contd..3) 105

Table 86: Products under Development by Companies, H2 2016 (Contd..4) 106

Table 87: Products under Development by Companies, H2 2016 (Contd..5) 107

Table 88: Products under Investigation by Universities/Institutes 108

Table 89: Products under Investigation by Universities/Institutes 109

Table 90: Products under Investigation by Universities/Institutes 110

Table 91: Products under Investigation by Universities/Institutes 110

Table 92: Products under Investigation by Universities/Institutes, H2 2016 111

Table 93: Age Related Macular Degeneration — Pipeline by AC Immune SA 112

Table 94: Age Related Macular Degeneration — Pipeline by Achillion Pharmaceuticals, Inc. 112

Table 95: Age Related Macular Degeneration — Pipeline by Aciont Inc. 113

Table 96: Age Related Macular Degeneration — Pipeline by AdAlta Pty Ltd. 113

Table 97: Age Related Macular Degeneration — Pipeline by Adverum Biotechnologies, Inc. 114

Table 98: Age Related Macular Degeneration — Pipeline by Aerie Pharmaceuticals, Inc. 114

Table 99: Age Related Macular Degeneration — Pipeline by Aerpio Therapeutics, Inc. 115

Table 100: Age Related Macular Degeneration — Pipeline by Alimera Sciences, Inc. 115

Table 101: Age Related Macular Degeneration — Pipeline by Alkeus Pharmaceuticals, Inc. 116

Table 102: Age Related Macular Degeneration — Pipeline by Allergan Plc 116

Table 103: Age Related Macular Degeneration — Pipeline by Allinky Biopharma 117

Table 104: Age Related Macular Degeneration — Pipeline by Alteogen Inc. 117

Table 105: Age Related Macular Degeneration — Pipeline by Amakem NV 118

Table 106: Age Related Macular Degeneration — Pipeline by Amarna Therapeutics B.V. 118

Table 107: Age Related Macular Degeneration — Pipeline by Ampio Pharmaceuticals, Inc. 119

Table 108: Age Related Macular Degeneration — Pipeline by Amyndas Pharmaceuticals LLC 119

Table 109: Age Related Macular Degeneration — Pipeline by Apellis Pharmaceuticals, Inc. 120

Table 110: Age Related Macular Degeneration — Pipeline by Apexigen, Inc. 120

Table 111: Age Related Macular Degeneration — Pipeline by Applied Genetic Technologies Corporation 121

Table 112: Age Related Macular Degeneration — Pipeline by Astellas Pharma Inc. 121

Table 113: Age Related Macular Degeneration — Pipeline by Benitec Biopharma Limited 122

Table 114: Age Related Macular Degeneration — Pipeline by BIOCAD 122

Table 115: Age Related Macular Degeneration — Pipeline by Biokine Therapeutics Ltd. 123

Table 116: Age Related Macular Degeneration — Pipeline by BioMAS Ltd. 123

Table 117: Age Related Macular Degeneration — Pipeline by Biomics Biotechnologies Co., Ltd. 124

Table 118: Age Related Macular Degeneration — Pipeline by Biophytis SAS 124

Table 119: Age Related Macular Degeneration — Pipeline by Boehringer Ingelheim GmbH 125

Table 120: Age Related Macular Degeneration — Pipeline by Caladrius Biosciences, Inc. 125

Table 121: Age Related Macular Degeneration — Pipeline by Catalyst Biosciences, Inc. 126

Table 122: Age Related Macular Degeneration — Pipeline by Cell Cure Neurosciences, Ltd. 126

Table 123: Age Related Macular Degeneration — Pipeline by Charlesson LLC. 127

Table 124: Age Related Macular Degeneration — Pipeline by Cipla Ltd. 127

Table 125: Age Related Macular Degeneration — Pipeline by Clanotech AB 128

Table 126: Age Related Macular Degeneration — Pipeline by Clearside BioMedical, Inc. 128

Table 127: Age Related Macular Degeneration — Pipeline by Clonz Biotech Private Limited 129

Table 128: Age Related Macular Degeneration — Pipeline by Coherus BioSciences, Inc. 129

Table 129: Age Related Macular Degeneration — Pipeline by Colby Pharmaceutical Company 130

Table 130: Age Related Macular Degeneration — Pipeline by Crinetics Pharmaceuticals, Inc. 130

Table 131: Age Related Macular Degeneration — Pipeline by Critical Pharmaceuticals Limited 131

Table 132: Age Related Macular Degeneration — Pipeline by Daiichi Sankyo Company, Limited 131

Table 133: Age Related Macular Degeneration — Pipeline by Delenex Therapeutics AG 132

Table 134: Age Related Macular Degeneration — Pipeline by Diffusion Pharmaceuticals Inc. 132

Table 135: Age Related Macular Degeneration — Pipeline by Digna Biotech, S.L. 133

Table 136: Age Related Macular Degeneration — Pipeline by Eleven Biotherapeutics Inc. 133

Table 137: Age Related Macular Degeneration — Pipeline by Elsalys Biotech SAS 134

Table 138: Age Related Macular Degeneration — Pipeline by Exonate Limited 134

Table 139: Age Related Macular Degeneration — Pipeline by F. Hoffmann-La Roche Ltd. 135

Table 140: Age Related Macular Degeneration — Pipeline by Foamix Pharmaceuticals Ltd. 135

Table 141: Age Related Macular Degeneration — Pipeline by Formycon AG 136

Table 142: Age Related Macular Degeneration — Pipeline by Gene Techno Science Co., Ltd. 136

Table 143: Age Related Macular Degeneration — Pipeline by Genentech, Inc. 137

Table 144: Age Related Macular Degeneration — Pipeline by GenSight Biologics S.A. 137

Table 145: Age Related Macular Degeneration — Pipeline by GlaxoSmithKline Plc 138

Table 146: Age Related Macular Degeneration — Pipeline by Grupo Ferrer Internacional, S.A. 138

Table 147: Age Related Macular Degeneration — Pipeline by GTx, Inc. 139

Table 148: Age Related Macular Degeneration — Pipeline by HanAll Biopharma Co., Ltd. 139

Table 149: Age Related Macular Degeneration — Pipeline by Huabo Biopharm Co., Ltd. 140

Table 150: Age Related Macular Degeneration — Pipeline by iCo Therapeutics Inc. 140

Table 151: Age Related Macular Degeneration — Pipeline by Icon Bioscience, Inc. 141

Table 152: Age Related Macular Degeneration — Pipeline by Iconic Therapeutics, Inc. 141

Table 153: Age Related Macular Degeneration — Pipeline by Innovent Biologics, Inc. 142

Table 154: Age Related Macular Degeneration — Pipeline by Intellect Neurosciences, Inc. 142

Table 155: Age Related Macular Degeneration — Pipeline by International Stem Cell Corporation 143

Table 156: Age Related Macular Degeneration — Pipeline by Ionis Pharmaceuticals, Inc. 143

Table 157: Age Related Macular Degeneration — Pipeline by Jeil Pharmaceutical Co., Ltd. 144

Table 158: Age Related Macular Degeneration — Pipeline by Johnson & Johnson 145

Table 159: Age Related Macular Degeneration — Pipeline by Kadmon Corporation, LLC 146

Table 160: Age Related Macular Degeneration — Pipeline by Kala Pharmaceuticals, Inc. 146

Table 161: Age Related Macular Degeneration — Pipeline by Kodiak Sciences, Inc. 147

Table 162: Age Related Macular Degeneration — Pipeline by LeadArtis S.L. 147

Table 163: Age Related Macular Degeneration — Pipeline by M's Science Corporation 148

Table 164: Age Related Macular Degeneration — Pipeline by Mabion SA 148

Table 165: Age Related Macular Degeneration — Pipeline by MacuCLEAR, Inc. 149

Table 166: Age Related Macular Degeneration — Pipeline by Mitotech S.A. 149

Table 167: Age Related Macular Degeneration — Pipeline by Mitsubishi Tanabe Pharma Corporation 150

Table 168: Age Related Macular Degeneration — Pipeline by Navigen Pharmaceuticals, Inc. 150

Table 169: Age Related Macular Degeneration — Pipeline by Navya Biologicals Pvt Ltd 151

Table 170: Age Related Macular Degeneration — Pipeline by Neovacs SA 151

Table 171: Age Related Macular Degeneration — Pipeline by Neumedicines Inc. 152

Table 172: Age Related Macular Degeneration — Pipeline by Neuroptis Biotech 152

Table 173: Age Related Macular Degeneration — Pipeline by Neurotech Pharmaceuticals, Inc. 153

Table 174: Age Related Macular Degeneration — Pipeline by Novartis AG 153

Table 175: Age Related Macular Degeneration — Pipeline by Ocular Therapeutix, Inc. 154

Table 176: Age Related Macular Degeneration — Pipeline by Ohr Pharmaceutical Inc. 154

Table 177: Age Related Macular Degeneration — Pipeline by Omeros Corporation 155

Table 178: Age Related Macular Degeneration — Pipeline by Ophthotech Corp. 155

Table 179: Age Related Macular Degeneration — Pipeline by Orphagen Pharmaceuticals, Inc. 156

Table 180: Age Related Macular Degeneration — Pipeline by Oxford BioMedica Plc 156

Table 181: Age Related Macular Degeneration — Pipeline by PanOptica, Inc. 157

Table 182: Age Related Macular Degeneration — Pipeline by Pfenex Inc. 157

Table 183: Age Related Macular Degeneration — Pipeline by Pfizer Inc. 158

Table 184: Age Related Macular Degeneration — Pipeline by Precision Ocular Ltd 158

Table 185: Age Related Macular Degeneration — Pipeline by Promedior, Inc. 159

Table 186: Age Related Macular Degeneration — Pipeline by pSivida Corp. 159

Table 187: Age Related Macular Degeneration — Pipeline by QLT Inc. 160

Table 188: Age Related Macular Degeneration — Pipeline by Quark Pharmaceuticals, Inc. 160

Table 189: Age Related Macular Degeneration — Pipeline by Ra Pharmaceuticals, Inc. 161

Table 190: Age Related Macular Degeneration — Pipeline by Regeneron Pharmaceuticals, Inc. 161

Table 191: Age Related Macular Degeneration — Pipeline by RegenxBio Inc. 162

Table 192: Age Related Macular Degeneration — Pipeline by Ribomic Inc. 162

Table 193: Age Related Macular Degeneration — Pipeline by RXi Pharmaceuticals Corporation 163

Table 194: Age Related Macular Degeneration — Pipeline by SanBio, Inc. 163

Table 195: Age Related Macular Degeneration — Pipeline by Santen Pharmaceutical Co., Ltd. 164

Table 196: Age Related Macular Degeneration — Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd. 165

Table 197: Age Related Macular Degeneration — Pipeline by SciFluor Life Sciences, LLC 165

Table 198: Age Related Macular Degeneration — Pipeline by Sirnaomics, Inc. 166

Table 199: Age Related Macular Degeneration — Pipeline by Stealth BioTherapeutics Inc. 166

Table 200: Age Related Macular Degeneration — Pipeline by Sucampo Pharmaceuticals, Inc. 167

Table 201: Age Related Macular Degeneration — Pipeline by Sumitomo Dainippon Pharma Co., Ltd. 167

Table 202: Age Related Macular Degeneration — Pipeline by Sun Pharma Advanced Research Company Ltd. 168

Table 203: Age Related Macular Degeneration — Pipeline by TRACON Pharmaceuticals, Inc. 169

Table 204: Age Related Macular Degeneration — Pipeline by TWi Pharmaceuticals, Inc. 170

Table 205: Age Related Macular Degeneration — Pipeline by Tyrogenex, Inc. 170

Table 206: Age Related Macular Degeneration — Pipeline by VasGene Therapeutics, Inc. 171

Table 207: Age Related Macular Degeneration — Pipeline by Wellstat Ophthalmics Corporation 171

Table 208: Age Related Macular Degeneration — Pipeline by Xbrane Biopharma AB 172

Table 209: Diabetic Retinopathy — Pipeline by Acucela Inc. 173

Table 210: Diabetic Retinopathy — Pipeline by Aerie Pharmaceuticals, Inc. 173

Table 211: Diabetic Retinopathy — Pipeline by Aerpio Therapeutics, Inc. 174

Table 212: Diabetic Retinopathy — Pipeline by Antisense Therapeutics Limited 174

Table 213: Diabetic Retinopathy — Pipeline by BCN Peptides, S.A. 175

Table 214: Diabetic Retinopathy — Pipeline by Biomar Microbial Technologies 175

Table 215: Diabetic Retinopathy — Pipeline by Charlesson LLC. 176

Table 216: Diabetic Retinopathy — Pipeline by Coherus BioSciences, Inc. 176

Table 217: Diabetic Retinopathy — Pipeline by Crinetics Pharmaceuticals, Inc. 177

Table 218: Diabetic Retinopathy — Pipeline by Diffusion Pharmaceuticals Inc. 177

Table 219: Diabetic Retinopathy — Pipeline by Dimerix Bioscience Pty Ltd 178

Table 220: Diabetic Retinopathy — Pipeline by Dynamis Therapeutics, Inc. 178

Table 221: Diabetic Retinopathy — Pipeline by EyeGene, Inc. 179

Table 222: Diabetic Retinopathy — Pipeline by Foresee Pharmaceuticals, LLC 179





1.2 List of Figures

Figure 1: Number of Products under Development for Age Related Macular Degeneration 18

Figure 2: Number of Products under Development for Age Related Macular Degeneration — Comparative Analysis 19

Figure 3: Number of Products under Development for Diabetic Retinopathy 20

Figure 4: Number of Products under Development for Diabetic Retinopathy — Comparative Analysis 21

Figure 5: Number of Products under Development for Diabetic Macular Edema 22

Figure 6: Number of Products under Development for Diabetic Macular Edema — Comparative Analysis 23

Figure 7: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) 24

Figure 8: Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) — Comparative Analysis 25

Figure 9: Number of Products under Development for Glaucoma, H2 2016 26

Figure 10: Number of Products under Development for Glaucoma — Comparative Analysis, H2 2016 27

Figure 11: Number of Products under Development by Companies 28

Figure 12: Number of Products under Development by Companies 39

Figure 13: Number of Products under Development by Companies 42

Figure 14: Number of Products under Development by Companies 46

Figure 15: Number of Products under Development by Companies, H2 2016 50

Figure 16: Number of Products under Investigation by Universities/Institutes 56

Figure 17: Number of Products under Investigation by Universities/Institutes 57

Figure 18: Number of Products under Investigation by Universities/Institutes, H2 2016 58

Figure 19: Comparative Analysis by Late Stage Development 60

Figure 20: Comparative Analysis by Clinical Stage Development 61

Figure 21: Comparative Analysis by Early Stage Products 62

Figure 22: Comparative Analysis by Clinical Stage Development 64

Figure 23: Comparative Analysis by Early Stage Products 65

Figure 24: Comparative Analysis by Late Stage Development 66

Figure 25: Comparative Analysis by Clinical Stage Development 67

Figure 26: Comparative Analysis by Early Stage Products 68

Figure 27: Comparative Analysis by Late Stage Development 69

Figure 28: Comparative Analysis by Clinical Stage Development 70

Figure 29: Comparative Analysis by Early Stage Products 71

Figure 30: Comparative Analysis by Late Stage Development, H2 2016 72

Figure 31: Comparative Analysis by Clinical Stage Development, H2 2016 73

Figure 32: Comparative Analysis by Early Stage Products, H2 2016 74

Figure 33: Comparative Analysis by Unknown Stage Development, H2 2016 75

Figure 34: Assessment by Monotherapy Products 290

Figure 35: Number of Products by Top 10 Targets 292

Figure 36: Number of Products by Stage and Top 10 Targets 292

Figure 37: Number of Products by Top 10 Mechanism of Actions 300

Figure 38: Number of Products by Stage and Top 10 Mechanism of Actions 300

Figure 39: Number of Products by Top 10 Routes of Administration 306

Figure 40: Number of Products by Stage and Top 10 Routes of Administration 306

Figure 41: Number of Products by Top 10 Molecule Types 308

Figure 42: Number of Products by Stage and Top 10 Molecule Types 308

Figure 43: Assessment by Monotherapy Products 310

Figure 44: Number of Products by Top 10 Targets 311

Figure 45: Number of Products by Stage and Top 10 Targets 311

Figure 46: Number of Products by Top 10 Mechanism of Actions 315

Figure 47: Number of Products by Stage and Top 10 Mechanism of Actions 315

Figure 48: Number of Products by Top 10 Routes of Administration 319

Figure 49: Number of Products by Stage and Top 10 Routes of Administration 319

Figure 50: Number of Products by Top 10 Molecule Types 321

Figure 51: Number of Products by Stage and Top 10 Molecule Types 321

Figure 52: Assessment by Monotherapy Products 322

Figure 53: Number of Products by Top 10 Targets 324

Figure 54: Number of Products by Stage and Top 10 Targets 324

Figure 55: Number of Products by Top 10 Mechanism of Actions 328

Figure 56: Number of Products by Stage and Top 10 Mechanism of Actions 328

Figure 57: Number of Products by Routes of Administration 331

Figure 58: Number of Products by Stage and Routes of Administration 331

Figure 59: Number of Products by Molecule Types 333

Figure 60: Number of Products by Stage and Molecule Types 333

Figure 61: Assessment by Monotherapy Products 335

Figure 62: Number of Products by Top 10 Targets 336

Figure 63: Number of Products by Stage and Top 10 Targets 336

Figure 64: Number of Products by Top 10 Mechanism of Actions 342

Figure 65: Number of Products by Stage and Top 10 Mechanism of Actions 342

Figure 66: Number of Products by Top 10 Routes of Administration 349

Figure 67: Number of Products by Stage and Top 10 Routes of Administration 349

Figure 68: Number of Products by Molecule Types 351

Figure 69: Number of Products by Stage and Molecule Types 351

Figure 70: Assessment by Monotherapy Products, H2 2016 353

Figure 71: Assessment by Combination Products, H2 2016 354

Figure 72: Number of Products by Top 10 Targets, H2 2016 355

Figure 73: Number of Products by Stage and Top 10 Targets, H2 2016 355

Figure 74: Number of Products by Top 10 Mechanism of Actions, H2 2016 362

Figure 75: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 362

Figure 76: Number of Products by Top 10 Routes of Administration, H2 2016 369

Figure 77: Number of Products by Stage and Top 10 Routes of Administration, H2 2016 369

Figure 78: Number of Products by Top 10 Molecule Types, H2 2016 371

Figure 79: Number of Products by Stage and Top 10 Molecule Types, H2 2016 371

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus